Unable to display view head.php file not found.
 
American Journal of Medicine
 

Hylek - Prevention and Treatment of Venous Thromboembolism - Figure 13
EINSTEIN-DVT, EINSTEIN-PE, RE-COVER

Figure 13 shows a pooled analysis of data from the EINSTEIN DVT, EINSTEIN PE, and RE-COVER trials.[7]  Dr. Eikelboom discusses these trials and their results in-depth in his presentation.  The Forest plot in the right-hand side of this Figure shows that these agents are non-inferior to dose-adjusted warfarin, or are relatively the same; however the value for most of the risk ratios are close to the line of unity and all of the confidence-interval lines cross the line, which means that there is not really an overwhelmingly clear superiority for any of these agents over dose-adjusted warfarin.  Hylek E. Am J Med 2013; published on-line at http://education.amjmed.com/00000. 

References

[7] Adam SS, McDuffie JR., Ortel TL, Williams Jr, JW. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: A systematic review. Ann Intern Med. 2012;157:796-807.

Unable to display view foot.php file not found.